静脉活性药物在慢性静脉疾病治疗中的作用
本综述评估静脉活性化合物(VACs)治疗慢性静脉疾病(CVD)的作用机制与疗效证据,采用GRADE分级评价证据质量。MPFF与假叶树提取物联合橙皮苷甲基查尔酮及抗坏血酸的证据质量最高(多为A级);MPFF、舒洛地特和己酮可可碱对静脉性溃疡的辅助治疗效果最佳(A级证据)。
要点
- VACs通过保护内皮屏障、促进淋巴引流、减轻水肿、改善静脉张力等机制发挥作用
- MPFF与假叶树提取物复方在改善CVD症状与水肿方面证据质量最高,多为A级
- MPFF、舒洛地特、己酮可可碱是静脉性溃疡最有效的辅助治疗,证据A级
核心结论
- 现有科学证据为将VACs纳入CVD综合治疗方案提供了充分依据,可与介入治疗及压力治疗等非介入方法联合以优化患者结局并改善生活质量。
研究设计与样本
- 本综述检索并评价VACs作用机制及疗效的科学证据,优先采用系统评价、荟萃分析和随机对照试验,证据质量按GRADE方法分为A(高)、B(中)、C(低至极低)三级。
主要发现
- 静脉活性药物作用相似,包括封闭内皮屏障、增强淋巴引流、减轻水肿、改善静脉张力、抑制白细胞黏附于静脉壁/瓣膜及炎症介质释放、降低血黏度、促进红细胞变形能力。
- VACs改善CVD症状(疼痛、痉挛、沉重感)和肿胀或水肿的证据存在一定差异。
- MPFF和假叶树提取物联合橙皮苷甲基查尔酮及抗坏血酸具有最高的、多为A级的证据质量。
- 静脉性溃疡中,MPFF、舒洛地特和己酮可可碱是最有效的辅助治疗,证据等级为A。
关键数值与推荐
- 证据质量采用GRADE方法:A(高)、B(中)、C(低至极低)。
- MPFF与假叶树提取物联合橙皮苷甲基查尔酮及抗坏血酸在CVD症状和水肿方面证据质量最高,多为A级。
- MPFF、舒洛地特和己酮可可碱在静脉性溃疡辅助治疗中证据等级为A。
临床怎么用
- VACs可纳入CVD综合治疗方案,与已确立的介入治疗和压力治疗等非介入方法联合使用,以优化患者结局并改善生活质量。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic venous disease (CVD) is a major global health issue, affecting millions of people and contributing to significant morbidity and economic strain. The condition's pathophysiology is complex, involving both mechanical and biochemical processes that lead to venous reflux, obstruction, and chronic inflammation. This review focuses on the role of venoactive compounds (VACs), also known as venoactive drugs in Europe and other parts of the world, in managing CVD. The aim was to review the scientific evidence and to define the role of VACs within the comprehensive treatment algorithm for CVD, alongside established and well adopted interventional therapies and noninterventional therapies such as compression. METHODS: The review of the scientific evidence was done on VACs mechanism of action and efficacy in alleviating CVD symptoms, reducing swelling or venous edema, and improving healing of venous leg ulcers. Whenever available, systematic reviews, meta-analyses and randomized controlled trials were used. The quality of evidence assessment followed the GRADE methodology from A (high), B (moderate), to C (low to very low) quality. RESULTS: Venoactive drugs or compounds share similar effects, such as sealing the endothelial barrier, enhancing lymphatic drainage, reducing edema, improving venous tone, inhibiting leukocyte adhesion to vein walls/valves and inflammatory mediator release, lowering blood viscosity, and promoting red blood cell flexibility. Scientific evidence on the VACs effectiveness on CVD symptoms (pain, cramps, and heaviness) and swelling or edema have shown some variability. Micronized purified flavonoid fraction (MPFF) and Ruscus extract combined with hesperidin methyl chalcone and ascorbic acid had the highest, mostly level A, quality of evidence. In venous leg ulcers, micronized purified flavonoid fraction, sulodexide, and pentoxifylline were the most effective adjunctive treatments, with evidence level A. CONCLUSIONS: The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and noninterventional approaches like compression, to optimize patient outcomes and improve quality of life.
引用
- Gloviczki ML, Kakkos SK, Urbanek T, et al. The role of venoactive compounds in the treatment of chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 40348378. doi:10.1016/j.jvsv.2025.102258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。